Skip to main content

Barrett Esophagus: Updated Guideline Recommendations

Considerable controversy surrounds the cost-effectiveness of screening and surveillance for Barrett esophagus (BE) as well as the role of ablative therapies aimed at decreasing the related esophageal adenocarcinoma (EAC) risk. The ACG has evaluated the most current published clinical reports on this topic and now offers evidence-based, weighted recommendations on current best practice – See more at:

Disclaimer: This information is for educational purposes only, It is not to diagnose or treat your disease. If you do use the information contained on this web site without the approval of a health professional, you are prescribing for yourself, which is your constitutional right, but the author(s) and webmaster assume no responsibility

© 2024 Esophageal Cancer Education Foundation- by domino